Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phenoxodiol with Cisplatin or Paclitaxel in Refractory Ovarian Cancer
NCT00091377Phase 2Completed
- Sponsor
- MEI Pharma
- Start
- Aug 2004
- Primary completion
- Dec 2007
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of idronoxil in ovarian epithelial cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by MEI Pharma. Primary endpoints: Safety and tolerability at 6 months and Tumor Response at 6 months. Started Aug 2004; status: completed.
02
Drugs
idronoxil
03
Conditions
ovarian epithelial cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00091377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00091377.